Stay updated on Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.

Latest updates to the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe update shows a minor revision from v3.3.1 to v3.3.2. No substantive study content or user-facing features appear to be affected.SummaryDifference0.0%

- Check21 days agoChange DetectedA new page revision label was added (v3.3.1) replacing the previous v3.2.0. There is no evident change to the study details, eligibility criteria, or outcomes in the visible content.SummaryDifference0.0%

- Check29 days agoChange DetectedThe government funding lapse notice was removed from the page. It previously warned that information may not be up to date and that inquiries could be delayed.SummaryDifference0.3%

- Check43 days agoChange DetectedNo significant changes detected in the Study Details page for NCT03743662; the study’s core content and structure appear unchanged compared to the previous view. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor changes: version updated to v3.2.0 and a prominent notice about government funding and operating status. Removed reference to v3.1.0.SummaryDifference4%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.